63 related articles for article (PubMed ID: 3891854)
1. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Aug; 135(2):1488-97. PubMed ID: 3891854
[TBL] [Abstract][Full Text] [Related]
2. Effect of albumin fusion on the biodistribution of interleukin-2.
Yao Z; Dai W; Perry J; Brechbiel MW; Sung C
Cancer Immunol Immunother; 2004 May; 53(5):404-10. PubMed ID: 14624312
[TBL] [Abstract][Full Text] [Related]
3. Purified mouse mammary tumor and lymphoid cells in immune assays.
Blazar BA; Vanky F; Klein E
Cancer Immunol Immunother; 1984; 18(3):174-8. PubMed ID: 6568874
[TBL] [Abstract][Full Text] [Related]
4. Distinct biological activities of recombinant forms of human interleukin-2 in vivo.
Lentsch AB; Nakagawa K; Yoshidome H; Gerassimides A; Miller FN; Edwards MJ
Cancer Immunol Immunother; 1997 Jan; 43(6):331-6. PubMed ID: 9067404
[TBL] [Abstract][Full Text] [Related]
5. Memory CD4 T cell-derived IL-2 synergizes with viral infection to exacerbate lung inflammation.
McKinstry KK; Alam F; Flores-Malavet V; Nagy MZ; Sell S; Cooper AM; Swain SL; Strutt TM
PLoS Pathog; 2019 Aug; 15(8):e1007989. PubMed ID: 31412088
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.
Pautier P; Locher C; Robert C; Deroussent A; Flament C; Le Cesne A; Rey A; Bahleda R; Ribrag V; Soria JC; Vassal G; Eggermont A; Zitvogel L; Chaput N; Paci A
Oncoimmunology; 2013 Feb; 2(2):e23079. PubMed ID: 23525192
[TBL] [Abstract][Full Text] [Related]
7. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.
Shimizu K; Fields RC; Giedlin M; Mulé JJ
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2268-73. PubMed ID: 10051630
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.
Helfand SC; Soergel SA; MacWilliams PS; Hank JA; Sondel PM
Cancer Immunol Immunother; 1994 Aug; 39(2):84-92. PubMed ID: 8044833
[TBL] [Abstract][Full Text] [Related]
9. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
[No Abstract] [Full Text] [Related]
10. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model.
Katre NV; Knauf MJ; Laird WJ
Proc Natl Acad Sci U S A; 1987 Mar; 84(6):1487-91. PubMed ID: 3494243
[TBL] [Abstract][Full Text] [Related]
11. Recruitment of inflammatory cells to a tumor deposit potentiates the immunotherapeutic effects of interleukin-2.
Steller EP; Eggermont AM; Matthews W; Sugarbaker PH
Cancer Immunol Immunother; 1986; 23(3):165-8. PubMed ID: 3491680
[TBL] [Abstract][Full Text] [Related]
12. Effect of T cell modulation on the translocation of bacteria from the gut and mesenteric lymph node.
Maddaus MA; Wells CL; Platt JL; Condie RM; Simmons RL
Ann Surg; 1988 Apr; 207(4):387-98. PubMed ID: 3281611
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model.
Eggermont AM; Sugarbaker PH
Br J Cancer; 1988 Oct; 58(4):410-4. PubMed ID: 3264714
[TBL] [Abstract][Full Text] [Related]
14. In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models.
Eggermont AM; Sugarbaker PH; Marquet RL; Jeekel J
Cancer Immunol Immunother; 1988; 26(1):23-30. PubMed ID: 3257900
[TBL] [Abstract][Full Text] [Related]
15. Effect of recombinant human interleukin 2 on the growth of a BALB/c sarcoma induced by Moloney murine sarcoma virus.
Mitsunaga S; Kimura H; Yamaguchi Y; Mikata A
Jpn J Cancer Res; 1988 Aug; 79(8):965-72. PubMed ID: 3141331
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of solid tumor by intratumoral infusion of lymphokine-activated killer cells.
Yamaki T; Ibayashi Y; Nakamura T; Shijubo N; Daibo M; Kawahara T; Hashi K
Jpn J Cancer Res; 1988 Aug; 79(8):903-8. PubMed ID: 3141326
[TBL] [Abstract][Full Text] [Related]
17. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.
Rosenberg SA
Ann Surg; 1988 Aug; 208(2):121-35. PubMed ID: 3041925
[TBL] [Abstract][Full Text] [Related]
18. Association of reduced interleukin-2 production with genetic susceptibility to Pichinde virus in inbred strains of hamsters.
Wright KE; Rosenthal KL; Rawls WE
Arch Virol; 1987; 92(3-4):197-209. PubMed ID: 3028332
[TBL] [Abstract][Full Text] [Related]
19. Effects of radiation on host-tumor interactions using the multicellular tumor spheroid model.
Wilson KM; Lord EM
Cancer Immunol Immunother; 1986; 23(1):20-4. PubMed ID: 2876773
[TBL] [Abstract][Full Text] [Related]
20. Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.
Thatcher N; Dazzi H; Johnson RJ; Russell S; Ghosh AK; Moore M; Chadwick G; Craig RD
Br J Cancer; 1989 Nov; 60(5):770-4. PubMed ID: 2803954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
